Podcasts about ramasamy

SRIVARU Holdings CEO Mohan Ramasamy joined Steve Darling from Proactive to share news the company has announced that it has successfully completed the internal testing of its PRANA 2.0 electric motorcycle, resulting in a full production model being submitted for final certification by applicable road and safety authorities. Additionally, the Company reports that its complete supply network is in place for production of the PRANA 2.0 upon final certification. Ramasamy told Proactive completion of the production version of Prana 2.0 marks a major milestone for SRIVARU. Following successful internal testing this news model boasts several notable features, including an expected 20% longer driving range compared to its predecessor. As a result, the PRANA 2.0 model can cover a distance of up to 250km on a single charge. The new model also includes extended battery life with components from BYD, and advanced motor technology adopted from aerospace applications. These improvements are part of SRIVARU's strategy to ensure product reliability and efficiency. Prana 2.0 is expected to reach consumers as early as the next month. Ramasamy draws from his Tesla experience and the semiconductor industry's scale for future product development and company expansion strategies. #proactiveinvestors #srivaruholdingslimited #nasdaq #svmh #svmhw #MohanrajRamasamy, #ElectricMotorcycles, #EVIndia, #PranaMotorcycle, #SustainableTransport, #ElectricVehicle, #TeslaAlumni, #BatteryTechnology, #MotorcycleInnovation, #EVMarket, #CleanEnergy, #Prana2.0, #ElectricBike, #MotorcycleTechnology, #AdvancedMotorcycles, #EnvironmentalImpact, #BYDBatteries, #EngineeringExcellence, #StartupGrowth #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Farah Rahman is a fourth-year medical student and a Las Vegas native who has traversed nearly every corner of the United States, from the Bronx and New Haven to Miami and San Diego. Entering medical school at Stritch with a background in public health and health policy, Farah obtained her MPH from the Yale School of Public Health. She is driven by a natural inclination to alleviate health disparities and work within a human centered framework to improve patient outcomes. Her natural tenacity, sociability, and drive to bring more women of color in previously male dominated fields introduced her to urology as a first year med student. During her first year of med school, Farah discovered her passion for urology, a field she found to be characterized by a harmonious blend of tradition and diversity. Notably, Farah took a year off between her third and fourth years of medical school to delve into research at the University of Miami under Dr. Ramasamy as a MARS scholar. This transformative experience significantly influenced her match process and ultimately contributed to her success in this year's urology match. If you are interested in applying into urology or applying for a research year, feel free to reach out to Farah with either email (frahman3@luc.edu) or her twitter (@farahrahman23). Episode produced by: Emily Hagen Episode recording date: 02/20/2024 --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

Listen to this interview featuring Dr. Ranjith Ramasamy and Dr. Braian Ledesma, who discuss their recent article "Fertility outcomes in men with prior history of anabolic steroid use." A medical researcher and urologist, Dr. Ramasamy is known for academic contributions to reproductive medicine, including testosterone deficiency, regenerative therapy, erectile dysfunction, and prostate cancer studies. He is the recipient of American Society for Reproductive Medicine's Rosenwaks Young Investigator Award. He published a study in JAMA on the impact of COVID-19 vaccines on male fertility. He is the Director of the Reproductive Urology Fellowship program at the University of Miami's Miller School of Medicine. Read the article "Fertility outcomes in men with prior history of anabolic steroid use" : https://www.fertstert.org/article/S0015-0282(23)01882-4/fulltext View Fertility and Sterility at https://www.fertstert.org/  

The former Penang Deputy Chief Minister Dr P. Ramasamy, who claimed the interests of working class Malaysian Indians have been sidelined in multiracial parties, has launched a new political movement, Urimai. On this episode of #ConsiderThis Melisa Idris speaks to Dr P. Ramasamy, Chairman of Urimai's Interim Leadership Council.

Gov. Laura Kelly hired Vijay Ramasamy as a special adviser on water to assist with the Ogallala Aquifer and other issues. Ramasamy says his job "is to make water central to a lot of our conversations."

Entrepreneur Vivek Ramaswamy is on the NHJournal podcast, fresh from his debate with Rep. Ro Khanna (D-Calif.) at the New Hampshire Institute of Politics. The GOP POTUS candidate talks about the massive ideological divide that exists in American politics. He also shares what New Hampshire voters tell him they want to talk about, and he offers his take on the NH Dems' new push for more gun control in the wake of the horrific mass shooting in Maine.Also, the host's take on the current state of the First in the Nation primary, and the potential impact of Rep. Dean Phillips' candidacy on the Democratic race.Hosted by Michael GrahamSponsored by Perfect Smiles of Nashua.

Selva Ramasamy KC (King's Counsel) is a senior barrister, joint head of QEB Hollis Whiteman Chambers and an elected Master of the Bench for Inner Temple.   As a King's Counsel, Selva is one of the most senior barristers responsible for conducting some of the most serious and complex cases in the country. Selva was actually the first non white member of his Chambers in its history and now they are one of the most diverse groups of barristers in the country. Selva explains growing up in a mixed race background, spending much of his early childhood abroad until coming back to the UK and attending a boarding school at aged 11. He remembers learning quickly to persuade and influence when clearly different to all those around him and his early experiences of racism have led him to become an advocate for inclusion and diversity within the legal profession. We both remember our early years as student barristers and the small red handbook issued to us all titled 'Learning the Law' by Glanville Williams in which it suggested that women and those from ethnic minorities might consider choosing a different profession due to the difficulties of 'getting on' if not from the standard background and upbringing. Those words continue to provide Selva with the motivation to keep driving change and role modelling a more modern approach at the Bar. Selva's day to day life requires him to deal with people immersed in the most extreme of human emotions with liberty at stake, managing multiple stakeholders and communicating across abilities, cultures and agendas. Selva is very proud of the work being done by Inner Temple and the Sutton Trust to increase social mobility within the profession. Selva tells me that by 'looking different' he is able to dispel certain myths as regards who is and who could become a barrister. The Bar continues to make huge step changes including wellbeing in order to assist barristers cope with the graphic and often brutal nature of the cases they are dealing with day to day, week to week and month to month. This episode provides a unique insight into one of the most intriguing professions, often portrayed in TV and film for it's bizarre and dramatic moments. The reality is a profession of individuals working tirelessly to Bridge the Justice Gap for all of us. We also enjoy a moment of celebration as Selva and I recently won The Hargreaves Cup together which since 1950 has been awarded to the winning Tennis team between the four Inns of Court. Enjoy this episode. Watch & Subscribe:

Skelley talked with Len Berman and Michael Riedel about Trump skipping the first Republican debate. 7 candidates have made the debate so far. Pence, Christie, DeSantis, Ramasamy, Haley, Scott, Burgum.

MINISTRY OF CULTURE AND CRA RATHINAVANI COMMUNITY RADIO PRESENTED MERE MATTI MERE DESH CAMPAIGN INDIA'S FREEDOM FRIGHTER K.RAMASAMY SETIYAR'S SON R S SHAMUGAM SPEECH ABOUT HIS FATHER.

On this episode we're talking about posthumous sperm retrieval. To help us in this discussion is Doctor Ranjith Ramasam, who is Director of Reproductive Urology and Associate Professor, University of Miami in Florida. Link to Article: Let People Collect Sperm From the Dead | WIRED More information on these topics is at www.asrm.org Tell us your thoughts on the show by emailing asrm@asrm.org Please subscribe and rate the show on Apple Podcasts, Google Play or wherever you get your podcasts. ASRM Today Series Podcasts are supported in part by the ASRM Corporate Member Council.

Sridhar Ramasamy is an industry veteran with interdisciplinary knowledge across the pharmaceutical and manufacturing domains. Sridhar leads digital transformation, engineering, automation and data analytics. In this episode, Swami and Sridhar delve deep into -The Importance of an Engineer Understanding a Business Problem - Asking Stupid Questions - How to Handle Ambiguity - Having an Open Mind and Looking at Data - Doing Your Boss's Job - Mindset For Digital Transformation - Industry Economy to Knowledge Economy Factories - Mixing Pragmatism with Innovative Thinking & Business Reality for Digital Transformation - Mixing Engineering Skills and Business Strategy - Key to Building Digital Factories - KPI Requires Business Understanding and Knowledge - Specs and Siloed Processes - Digital Twins and Applying it to the Digital Knowledge Factories of Tomorrow - Multi-functional-multi-disciplinary Knowledge - Automation does not Reduce Jobs - Learnings from other Industries - How to Solve for a Problem not Invented as yet #digitalfactories #smartmanufacturing #reliabilityengineering, #lightsoutmanufacturing#dataanalytics #justintimeproduction #leanmanufacturing #pharma #sanofi #plantautomation #sixsigma #digitalmaturity #automation #industryeconomy #knowledgeeconomy #businessstrategy #digitaltwins #multidisciplinaryknowledge #multifunctional You can watch the full video episode on YouTube For show notes and earlier guest interviews, please visit ⁠www.contraminds.com⁠ To sign up for our weekly newsletter, please visit ⁠https://contraminds.substack.com/⁠ Connect with Sridhar: ⁠https://www.linkedin.com/in/sriramasamy/⁠ Connect with Swami: ⁠https://www.linkedin.com/in/sivaraman-swaminathan-9856501/⁠ Connect with Vignesh: ⁠https://twitter.com/hrorq⁠ Connect with us: LinkedIN: ⁠https://www.linkedin.com/company/contraminds/⁠ Instagram: ⁠https://www.instagram.com/contraminds/⁠ Facebook: ⁠https://www.facebook.com/contraminds⁠ Website: ⁠www.contraminds.com

42. எல்லாவகையிலும் ஒரு ராமசாமிக்கு இருக்குற தைரியம் தமிழ்நாட்டில் யாருக்கும் இல்லையே || Traffic Ramasamy is having courage Why not tamils || Kalaignar Speech 12012014

On this episode of BackTable Urology, Dr. Aditya Bagrodia, Dr. Ranjith Ramasamy, and medical student Farah Rahman discuss effective and meaningful ways to build a productive team in medicine. --- SHOW NOTES First, Dr. Ramasamy recounts his journey to becoming a mentor for medical students. Initially, he found difficulty in finding peer relationships in academic medicine, so he started mentoring medical students. After seeing one of his mentees help out another student, he saw a benefit in building his own team in order to indirectly help more students outside of the traditional one-on-one mentoring model. He explains which qualities are most important for team members to have and has an open door policy and open communication with every team member. Farah adds that including many stages of trainees in the team with different skill sets is also useful. She emphasizes the importance of collaboration as the foundation for a productive team. They also discuss ways to resolve conflicts, like communicating expectations about professional duties and checking in periodically and frequently with team members. Farah adds that mentors should know their mentees' strengths and weaknesses and steer them away from opportunities that are not helpful. Dr. Ramasamy notes that having a good work life balance and encouraging students to do the same is also beneficial. Finally, they discuss the value in branding a team and the power of social media to reach out to new team members and patients.

Country music in Nashville, Ramasamy has Neal's vote, State income tax, Screw Twitter, and more. Take a listen! Atlanta's ONLY All Conservative News & Talk Station.: https://www.xtra1063.com/See omnystudio.com/listener for privacy information.

#kiranprabha #teluguhistory #history Colonel Colin Mackenzie CB (1754–1821) was Scottish army officer in the British East India Company who later became the first Surveyor General of India. He was a collector of antiquities and an orientalist. He surveyed southern India, making use of local interpreters and scholars to study religion, oral histories, inscriptions and other evidence, initially out of personal interest, and later as a surveyor. Kavali Borrayya was a Telugu Scholar who helped Mackenzie in his collection of antiquities and interpreting them. Borrayya died at a very young age of 26 years. Mackenzie and Borrayya are the primary reason for today's south India history documentation. Borrayya's brothers Lakshmaiah and Ramasamy also helped Mackenzie after Borrayya's death. In this research based talk show, KiranPrabha covered the life sketches of these people as well as their selfless service towards collecting antiquities which finally helped historians.

This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!In part 1 we talked about a request that has been submitted for the World Health Organization (WHO) to add diet drugs (specifically GLP1 agonists like Novo Nordisk's Saxenda and Wegovy) to their list of “essential medicines.” We discussed who was making this request and the justification that they were using. In part 2 we took a deeper dive into the research that they used to try to support this request, and in this final installment, we will look at the research around efficacy, harm, and cost-effectiveness.First I'll offer a summary for each issue and then I'll give a breakdowns of the research that they cite.  Just a quick reminder that this request is asking the World Health Organization (WHO) to add these drugs to their list of “essential medications” globally.Before we get into the sections, I want to mention two overarching issues that are found throughout the entirety of this request and the studies that are used to support it.First, in general, a belief has been fomented (predominantly by those in the weight loss industry) that being higher-weight is so terrible then it's worth “throwing anything at the problem.” This leads to acceptance of poor, short-term, and/or incomplete data as “good enough” to foist recommendations onto higher-weight people, which means that part of weight stigma in healthcare is that higher-weight people are afforded less right to ethical, evidence-based medicine than thinner people.Second, is clinging to correlation (without any mechanism of causation) when it comes to weight, health, and health outcomes, including the abject failure to consider confounding variables. So throughout these studies “being higher-weight is associated with [health issue(s)]” stated uncritically in support of weight loss interventions. There is an utter failure to explore the idea that the reason for the outcome differences is not weight itself but, instead, exposure to weight stigma, weight cycling (which these medications actually perpetuate by their own admission,) and healthcare inequalities.  Issues with research supporting effectiveness, harms, and benefitsStudy Duration:This is the main issue. While there was one study that went up to 106 weeks, the vast majority of the studies are between 14 and 56 weeks. We know that these drugs can have significant, even life-threatening side effects (earning them the FDA's strongest warning.) 14-56 weeks is not not nearly enough time to capture the danger of long-term effects, or to capture long-term trends around weight loss/weight regain.Study PopulationMany of the studies included have small samples. Many have study populations are overwhelmingly white, which is a huge issue when making a global recommendations.Small effect and overlapMany of the studies show only a bit of weight loss (often 15lbs or less) and often there was overlap in weight lost between the treatment group and the placebo group. Even using the “ob*sity” construct that this request is based on, for many people, this amount of weight loss wouldn't even change their “class” of “ob*sity.”Failure to capture adverse eventsMuch of the research they use to support their claims of safety didn't actually capture individual adverse events or serious adverse events. Often they only captured subjects who reported leaving treatment due to side effects.Issues with research supporting cost effectivenessThe cost-effectiveness analyses they cite are based on Quality Adjusted Life Years (QALYs). This is a measurement of the effectiveness of a medical intervention to lengthen and/or improve patients' lives.The calculation for this is [Years of Life * Utility Value = #QALY]So if a treatment gives someone 3 extra years of life with a Health-Related Quality of Life (HRQL) score of 0.7, then the treatment is said to generate 2.1 [3 x 0.7] QALYs.This is a complicated and problematic concept that deserves its own post sometime in the future, but looking just at this request I think it's important to note that they are working on two main unproven assumptions:1. That being higher weight causes lower health-related quality of life and/or shorter life span (rather than any lower HRQL being related to experiences that higher-weight people have including weight stigma, weight cycling, healthcare inequalities et al.) 2. That this treatment induces weight loss and/or health benefits that increase the life span and/or health-related quality of life of those who take it.I don't believe either of these assumptions are proven by the material cited in the request to the WHO. Specifically, it's very possible that it's not living in a higher-weight body, but rather the experiences that higher-weight people are more likely to have (weight stigma, weight cycling, healthcare inequalities) that impact their HRQL.Further, the short-term efficacy data available (and Novo Nordisk's own admission about high rates of regain) fall far short of proving any assumptions about these drugs ability to actually improve or extend life. Further, the failure of the literature to adequately capture negative side effects of the drugs, both short and long-term, means that this calculation cannot be properly made.Incremental Cost-Effectiveness Ratio (ICER)ICER is how QALYs are turned into a monetary value. It is calculated by dividing the difference in total costs by the difference in the chosen measure of health outcome or effect.[(Cost of intervention A -Cost of Intervention B) / (Effectiveness of Intervention A – Effectiveness of Intervention B)]The result is a ratio of extra cost per extra unit of health effect of a more vs less expensive treatment which can then be measured in QALYs.Again, this is worthy of its own post because there are all kinds of ethical issues around things like how we value life, how we define “healthy” and the ethics of determining whether or not prolonging someone's life is “cost effective.” I'm not going to do a deep dive into that today, but I do want to note that it is a serious issue in these kinds of calculations.In this specific case, even if one was to get past the ethical issues, an accurate calculation is impossible to make on both of the measures of the equation.Cost of these drugs varies wildly between countries and sometimes within countries because, for example, Novo Nordisk is a for-profit corporation whose goal is to create as much profit as possible.  Per the WHO request letter, the monthly cost of liraglutide is $126 in Norway and $709 in the US. Semaglutide is $95 per 30 days in Turkey, but $804 per 30 days in US.When it comes to effectiveness of the treatment, again, there is virtually no long-term data. We do know that in Novo Nordisk's own studies, weight is regained rapidly and cardiometabolic benefits are lost when the drugs are discontinued and even when people stay on the drugs, weight loss levels off after about a year, at 68 weeks weight cycling begins, and at 104 weeks (when follow-up ended) weight was trending up. It's possible that these drugs are utterly ineffective over the long-term and/or that the prevalence of long-term side effects renders any treatment effects moot. We simply do not know.I do not think that this is a remotely appropriate basis from which to request that these drugs be declared globally essential by the WHO.Here are the citation breakdowns. These are not deep dives since there are enough issues with the research on a simple surface analysis.Breakdowns of evidence of comparative effectivenessEffects of liraglutide in the treatment of ob*sity: a randomised, double-blind, placebo-controlled study, Astrup et al.)This is a 20-week study funded by Novo Nordisk. It included 564 people on various doses of liraglutide and a placebo group who didn't get the drug and a group on orlistat. There were no more than 90-98 people in each group.The study explains “Participants on liraglutide lost significantly more weight than did those on placebo” by which they meant that those on the highest dose of liraglutide lose about 9.7lbs more than those on the placebo over the 20 weeks.III LEAD studiesThese are four studies that look at liraglutide in combination with other drugs for the treatment of Type 2 Diabetes that also included some information on weight changes. One was 52 weeks, the others were  26, the maximum amount of weight lost was only about 5lbs.   The first [Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU), Marre et al] was a study that looked at the efficacy of adding liraglutide or rosiglitazone 4 to glimiperide in subjects with Type 2 Diabetes to test effects on blood sugar and body size.The study followed 1041 adults for 26 weeks. The study found that those on .6mg of liraglutide gained 0.7kg, those on 1.2mg gained 0.3kg, and those on 1.8mg of liraglutide lost 0.2kg, while those on placebo lost 0.1kg.The second [Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009. 32(1): p. 84-90. Nauck, M., et al.,]looked at the efficacy of adding liraglutide to metformin therapy for those with Type 2 Diabetes. They found that over the 26-week study those on liraglutide lost 1.8 ± 0.2, 2.6 ± 0.2, and 2.8 ± 0.2 kg for 0.6, 1.2, and 1.8 mg doses. Those on placebo lost 1.5 ± 0.3kg.The third [Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 2009. 373(9662): p. 473-81. Garber, A., et al.,] This was a study of the comparative effectiveness of Liraglutide versus glimepiride for type 2 diabetes, with small weight loss as an ancillary finding. Those in the liraglutide group lost an average of 2kg.The final study [Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Zinman et al.]  was a 26-week study with 533 total subjects. The goal was to study the efficacy of liraglutide when added to metformin and rosiglitazone for people with type 2 diabetes. They found that those on liraglutide lost between 0.7 and 2.3kg (1.5lbs to 5.1lbs) in 26 weeks.Meta-Analyses and Systematic Review FindingsEfficacy of Liraglutide in Non-Diabetic Ob*se Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Barboza, J.J., et al., None of the included studies were more than 56 weeks and one was only 14 weeks. One had as many as 3731 subjects, but one had only 40. Some had body weight loss as a primary outcome, but some did not. Maximum doses ranged from 1.8 to 3.0mg. The mean body weight reduction was  3.35 kg (7.4lbs) but in one study there was no difference in weight loss. The maximum difference was 6.3kg (13.9lbs)They also refer to Iqbal et al which we discussed in part 2.Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Vilsbøll, T., et al.The included studies are between 20 and 53 weeks long, and include some of the studies they already cited individually above. Of the 25 included studies only 3 had “ob*sity” as the main inclusion criteria, the rest were Type 2 Diabetes.The mean weight loss for those on the highest dose of the drug was between 0.2kg and 7.2kg. For those in the control group it was 2.9 kg, so there was actually overlap between the treatment and placebo groups.Summary of evidence of safety and harmsThey begin with the claim “The safety profile of GLP-1 receptor agonists is also well studied”To support this they cite: Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Ob*se with or without Diabetes: A Systematic Review and Meta-Analysis, Konwar, M., et al.,This included 14 total studies, many of which the authors of the WHO request had cited individually and were included in other systematic reviews and meta-analyses above. The smallest study included 19 people, the largest included 2,487. The total number of subjects was 4,142.Their conclusion was “Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or ob*sity regardless of diabetic status compared to placebo.”Their methodology says that they omitted studies from analysis due to “short duration.” They included studies that had a minimum of 12 weeks and a maximum of 56 weeks of follow-up.While they included 14 studies, only 11 of them actually included information about adverse events.In terms of adverse effects (AEs,) they found that the pooled estimate of nine studies in nondiabetic patients and two studies in diabetic patients revealed a significant proportion of patients experiencing the adverse events in liraglutide 3.0 mg group when compared with placebo., and the pooled estimate of the eleven studies showed that liraglutide 3.0 mg had higher risk of AEs compared to placebo.When it came to “serious adverse events” they found that there was a similar risk level between the drug and placebo groups, but remember that's for only 12 to 56 weeks, and Novo Nordisk is recommending that people take these drugs for the rest of their lives. A few months to a little over a year is not enough time to capture long-term serious adverse events.The efficacy and safety of liraglutide in the ob*se, non-diabetic individuals: a systematic review and meta-analysis. Zhang, P., et al.,This included five RCTs (which were included in various of the above systemic reviews and meta-analyses) ranging in follow-up from 14 to 56 weeks.The only adverse event information captured was the number of people who withdrew from treatment due to adverse events (which they found was similar between drug and placebo) and nausea (which was experienced more by people on the drug.)So, in addition to being short in duration, this was far from a comprehensive list of side effects. They made no attempt to capture serious adverse side effects and their short-term nature would have made this difficult anyway.Association of Pharmacological Treatments for Ob*sity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera, R., et al.This looked at weight loss and adverse events with a number of different weight loss drugs. Interestingly liraglutide did not show the highest amount of weight loss but was associated with the highest odds of adverse event–related treatment discontinuation. It should also be noted that high drop-out rates of 30-45% plagued all of the trials which the study authors admit means that “studies were considered to be at high risk of bias.“Given that those who drafted the WHO request are asking that these drugs be considered essential globally, it is disappointing that they included this study and didn't bother to mention this issue in their written request.This included 28 RCTs (most of which were included in other citations above) and only 3 that included liraglutide. They didn't capture individual adverse events, but only “Discontinuation of Therapy Due to Adverse Events.” They only evaluated a year of data so, again, while it is likely that these studies would have captured common adverse events had they bothered to try, there isn't long enough follow-up to have any information about serious (possibly life-threatening) long-term adverse events.Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Ob*sity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. Vosoughi, K., et al.,This study included 64 RCTs with durations from 12 to 160 weeks, with a median of 26 weeks. As is common in these studies, the majority of the sample (74.9%) was white.Like those above, they only looked at treatment discontinuation from adverse events, they did not capture specific adverse events (common or serious.) Of the seven GLP-1 drugs they tested, liraglutide was tied with taspoglutide for the highest discontinuation of treatment due to adverse events.The study authors also note that “Risk of bias was high or unclear for random sequence generation (29.7%), allocation concealment (26.6%), and incomplete outcome data (26.6%).”Breakdowns for Comparative Cost-effectiveness StudiesFirst, the WHO request authors themselves admit that when it comes to cost-effectiveness, “the analyses have generally been performed only for high-income countries.” This is significant since they are asking the WHO to consider these drugs essential for the entire world.It's also important to understand that none of the data looks at a comparison of cost effectiveness for weight-neutral health interventions to these drugs. Without that information there is no way to calculate actual “cost effectiveness” since it's possible that weight-neutral health interventions would have greater benefits with less risk and dramatically lower cost.  NICE's guidance:  Liraglutide for managing overweight and ob*sity Technology appraisal guidance [TA664]Published: 09 December 2020.Do recall that NICE is involved in the current scandal with Novo Nordisk for influence peddling.These guidelines are created based on a submission of evidence by Novo Nordisk. The committee's understanding of “clinical need” was based on the testimony of a single “patient expert” who “explained that living with ob*sity is challenging and restrictive. There is stigma associated with being ob*se.”Once again we see a rush to blame body size for any “challenges” and “restrictions” of living in a higher-weight body, accompanied by the immediate decision that those bodies should be subjected to healthcare interventions that risk their lives and quality of life in order to be made (temporarily, by Novo and NICE's own admission) thinner.  There did not seem to be a patient expert to discuss the weight-neutral options.It was not immediately apparent if the patient expert was provided/paid by Novo Nordisk, but they certainly forwarded their narrative that simply living in a higher-weight body is a disease requiring treatment.It should be noted that while the trial Novo Nordisk submitted covered a wider range of people, they specifically submitted for this recommendation only the subgroup of that population who were diagnosed with “ob*sity,”  pre-diabetes, and a “high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia.”So, even if we accept this guidance as true, the WHO Essential Medicines request applies to a population much wider than this and so this fails to justify the cost-effectiveness for that population.This guidance is also based on the costs associated with obtaining the drugs through a “specialist weight management service” since an agreement is in place for Novo Nordisk to give a discount to these services.In calculating the ICER per QALY gained, the recommendations note that “Because of the uncertainties in the modelling assumptions, particularly what happens after stopping liraglutide and the calculation of long-term benefits, the committee agreed that an acceptable ICER would not be higher than £20,000 per QALY gained”Again, this recommendation is based on a trial submitted by Novo Nordisk that included 3,721 people and lasted for three years, but only 800 met the criteria for this cost-effectiveness recommendation. The trial failed to show a significant reduction in cardiovascular events. Novo's calculation of risk reduction was based on surrogate outcomes, which NICE points out “introduces uncertainty because causal inference requires direct evidence that liraglutide reduces cardiovascular events. This was not provided in the company submission because of lack of long-term evidence.”The NICE committee admits “relying on surrogates is uncertain but accepted that surrogate outcomes were the only available evidence to estimate cardiovascular benefits.”I just want to point out that another option would be to refuse to experiment on higher-weight people without appropriate evidence.These cost-effectiveness calculations are based on someone using the drug for two years, with no actual data on reduction in cardiovascular events, and with the admitted assumption that “any weight loss returned to the base weight 3 years after treatment discontinuation.” Said another way, this committee decided that it was cost effective to spend up to £20,000 per QALY for people to take a weight loss drug with significant side effects for two years, with no direct evidence of reduced cardiovascular events, and with the acknowledgment that people will be gaining all of their weight back when they stop taking it.Those who wrote the request for WHO to consider these drugs “essential” chose to characterize this as “At the chosen threshold of £20,000 per quality-adjusted life year (QALY) gained, the report concluded that liraglutide is cost-effective for the management of ob*sity.” I do not think that is an accurate characterization of the findings.The request cites “A report by the Canadian Agency for Drugs and Technologies in Health (CADTH) found that compared to standard care, the ICER for liraglutide was $196,876 per QALY gained”For the US, they cite a study that found that to achieve ICERs between $100,000 and $150,000 perQALY or evLY gained, the health-benefit price benchmark range for semaglutide was estimated as $7500 - $9800 per year, which would require a discount of 28-45% from the current US net price.They also cite “Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and ob*sity in the United States, Kim et al.Let's take a look at their conflict of interest disclosure (emphasis mine)“Financial support for this research was provided by Novo Nordisk Inc. The study sponsor [that means Novo Nordisk] was involved in several aspects of the research, including the study design, the interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication.Dr Kim and Ms Ramasamy are employees of Novo Nordisk Inc. Ms Kumar and Dr Burudpakdee were employees of Novo Nordisk Inc at the time this study was conducted. Dr Sullivan received research support from Novo Nordisk Inc for this study. Drs Wang, Song, Wu, Ms Xie, and Ms Sun are employees of Analysis Group, Inc, who received consultancy fees from Novo Nordisk Inc in connection with this study.”Given that, you probably won't be shocked to learn that this concluded that Novo Nordisk's drug, semaglutide, was cost-effective. The reason I bolded the text above is that this study is based on modeling – they are taking what is, by their own admission, a “new drug” and making predictions for 30 years. Everything was simulated based on trial data (you know, those trials that we've been discussing that often have horrendous methodology…) and “other relevant literature.” The construction of the modeling and the interpretation of the results was directed by the company who stands to benefit financially from the findings, and carried out by that company's employees and consultants.  Also, and I'll just quote again here since I don't think I can improve on their text “Cost-effectiveness was examined with a willingness-to-pay (WTP) threshold of $150,000 per QALY gained” I do not think that this WTP is based on a global assessment.In their (and by their I mean Novo Nordisk's) modeling they find that semaglutide was estimated to improve QALYs by 0.138 to 0.925 and incur higher costs by $3,254 to $25,086 over the 30-year time horizon vs comparators.And, again, this is without any kind of actual long-term data. I think that the best way to characterize this information is “back of the envelope calculations” at best.To sum up, I do not think that the research they cite comes anywhere close to proving that these drugs have levels of efficacy, safety, or cost-effectiveness that warrant their addition to the WHO list of essential medicines. I believe that if the WHO grants this request I think it will be an affront to medical science, it will cheapen the concept of “essential medicines,” and it will harm untold numbers of higher-weight people all over the world.Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter and get special benefits! Click the Subscribe button below for details:Liked this piece? Share this piece:More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Boxer gives us an update on East Palestine and we get to know Vivek Ramaswamy, athor of Woke Inc., and Entrepenour. he's and Ohio native and resides in Upper Arlington.

Penang Deputy Chief Minister, Dr P.Ramasamy has called for the government to reform the civil service, saying that it was now dominated by Malays. This has received flak from both sides of the political divide. First, we discuss Dr P. Ramasamy's remarks. Then, we look at the political fallout from this, as well as the PM's response to it.Image Credit: Azami Adiputra, Shutterstock

"Under the Tree" is an initiative to re - live the child hood and our lives by relating to stories by great writers of yesteryears. The objective is to rekindle the interest of reading and showcase the Indian authors work which give rebirth to the tradition, culture. Spiritual series that is rich in Indian ethos along with Management aspects increase positivity which is much needed always..

#kiranprabha #sivajiganesan #veerapandiyakattabomman Veerapandiya Kattabomman is a 1959 Indian Tamil-language biographical war film produced and directed by B. R. Panthulu. The film stars Sivaji Ganesan, Gemini Ganesan, Padmini, S. Varalakshmi, and Ragini, with V. K. Ramasamy and Javar Seetharaman in supporting roles. Its soundtrack and score were composed by G. Ramanathan. KiranPrabha talks about the background story of this film making and many more interesting anecdots about this film.

An emotional story about the old woman and a young preganant woman

Vasunthara Ramasamy: "There are so many styles of chicken curry; there is even a white chicken curry. If Clarissa cooked that, people would say that that is not a Singaporean chicken curry. So what is Singaporean chicken curry? Do we have one? The consensus is that we can never have a national dish because it is very hard to represent Singapore. But why seek for singularity when you are so diverse? Why do we seek such homogenous experiences with Indian food?"Vasunthara Ramasamy, Culinary Teacher and Masterchef Singapore Season 2 Contestant, shares about feeling pride as a Singaporean Indian, plus: *No-grind thosai* *How we can bring Indian home dishes to the masses* *Singaporean Indian food as a diasporic cuisine* *How Singaporean history impacted Indian food in Singapore* *Sardine curry* *Caste and Indian food culture* *Sense of inferiority that Singaporean Indians feel towards their food* *How the palate of Singaporean Indians differ from Indians in India* *Fish head curry* *Caste in Singapore* *Homogenization of Indian food in Singapore and Malaysia* *The rise of curry powder* *The case for making your own curry powder and spice blends* *Grinding your own turmeric powder and asafoetida* *Preconceived idea that Indian cuisine is not on par with European cuisine* *The need for more champions of Indian food* *Singaporean chicken curry saga* *Fear of failure as Singaporeans* *Home-cooking* *Her Masterchef journey*Singapore Noodles: http://sgpnoodles.com/ @sgpnoodlesNewsletter: http://sgpnoodles.substack.com/

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: the Game of Thrones spinoff wraps up filming, the Halo TV Series will reveal Master Chief's face, the Sonic The Hedgehog 2 movie has a lot of reference to the original games and the Fallout TV Series found its actor to play the main character. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

Founded in 2014, Bengaluru-based drone tech startup Skylark Drones provides worksite intelligence to enable accurate business decision-making using drone data. Skylark Drones is involved in building core infrastructure for global drone ecosystems. Skylark Drones claims that it has worked with over 100 enterprises and executed over 20,000 autonomous flights via their platform, processing more than one million images since inception. The core products are Drone Mission Ops and Spectra. Drone Mission Ops is a full-stack drone flight solution that enables drone service providers, pilots, and enterprises to execute fast, accurate and seamless drone missions. Meanwhile, Spectra is an integrated drone data platform for enterprises to visualize their worksite and get AI-powered analytics for making better business decisions. Entrepreneurs Mughilan Thiru Ramasamy and Mrinal Pai have known each other since they were pursuing engineering degrees from RV College of Engineering. During their time at college, the duo was also a part of Team Vyoma, an aerodynamics club where they built unmanned aerial vehicles (UAVs). With a passion for innovations in the drone sector, the duo launched Bengaluru-based Skylark Drones to provide worksite intelligence and enable accurate business decision-making using drone data. --- Send in a voice message: https://anchor.fm/gmbwithkay/message

https://youtube.com/channel/UClwJVGgod172oL0_ITgWNrA https://www.facebook.com/arivalaipodcast/ https://www.instagram.com/arivalaipodcast?r=nametag https://open.spotify.com/show/0iQXWlfY01gIyQjQhDyJzK?si=po5iK42RTLmDm1BKxhr0kg&utm_source=copy-link&dl_branch=1

On the final episode of Hero Time for 2021, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: The first look at the new Spider Verse sequel, the Peacemaker series trailer shows its serious side, Charlie Cox returns as Daredevil and Cobie Smulders reprising her role in the Secret Invasion series. All on the final episode of Hero Time for 2021 with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: Former Bioware writer has opinions on the Mass Effect or Dragon Age TV show, the MCU's Daily Bugle has a TikTok account, Tom Holland remains in the MCU as Spider Man after all and George RR Martin begged HBO to do 10 seasons of Game Of Thrones. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: Letitia Wright's injuries were more serious than Marvel thought, Scarlett Johansson is working on a new Marvel project unrelated to her Black Widow character, Michael Keaton will reprise his Spider Man villain role and Activision Blizzard employees signed petitions to fire their CEO Bobby Kotick. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: Stranger Things Season 4 has a new trailer revealed, Black Panther 2's production came to a hult due to an injury on set, Dwayne Johnson's movies will not use rubber guns instead of real prop ones and Chris Columbus wants to direct the Harry Potter and the Cursed Child adaptation with the original trio. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

"Under the Tree" is an initiative to re - live the child hood and our lives by relating to stories by great writers of yesteryears. The objective is to rekindle the interest of reading and showcase the Indian authors work which give rebirth to the tradition, culture. Spiritual series that is rich in Indian ethos along with Management aspects increase positivity which is much needed always...

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: The new Witcher Season 2 trailer shows monsters, wars and magic, Amy Hennig is making a new Marvel game, CD Projekt Red delayed Cyberpunk 2077's new upgrades and Tom Holland pitched Sony on how Spider Man could've joined the Venomverse. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

Alan Crockett was joined by ACEC Young Professional of the Year Molly Dee Ramasamy from Jaros, Baum & Bolles, New York, NY. As head of deep carbon reduction at JB&B, Molly initiated a process of assessing how clients' buildings could conform to such a regulation.  She has successfully led and completed more than a dozen complex building decarbonization and building electrification studies for large commercial, institutional, and cultural buildings.

In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London, UK) and Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine and the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, USA) discuss their experience and views on choosing the best treatment every time in multiple myeloma. In this second episode, Dr. Richter and Dr. Ramasamy explore how to select the best treatment approach in the second-line setting and beyond. Firstly, they discuss at what point they consider a patient to actually be in relapse. They both believe that it’s important to stay on top of this incurable illness and act when there is a suspicion of relapse. However, the need to treat must be balanced with quality of life. They also take potential enrolment into a clinical trial into account in the treatment decision. The decision on which treatment option to select in the second line and beyond mostly depends on refractoriness to other drugs. With an increasing number of novel treatment options becoming available, choosing a regimen that does not contain a drug the patient is refractory to is becoming easier. Dr. Richter and Dr. Ramasamy discuss the challenges around these treatment decisions. Furthermore, they share their experiences with CAR-T and other T cell redirection therapies, and when to use it in the treatment sequence. The speakers conclude with a look into the future of myeloma treatment.

Dr. Ranjith Ramasamy explains the known effects of the COVID-19 virus and the pandemic on testosterone levels, vasculogenic erectile dysfunction, male fertility, and sexual practice patterns. Additionally, Dr. Ramaswamy uses evidence-based medicine to debunk myths about the adverse effects of the COVID-19 vaccine on men's health. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/7hBgDv --- SHOW NOTES In this episode of BackTable Urology, Dr. Aditya Bagrodia and Dr. Ranjith Ramasamy discuss the effects of the COVID-19 pandemic and COVID vaccines on various men's health topics, including testosterone levels, erectile dysfunction, and male fertility. First, Dr. Ramasamy discusses the effects of COVID-19 on hypogonadism. He notes that in the initial stages of the pandemic, many providers attributed low testosterone levels as result of a sedentary and less active lifestyle because of the lockdown. However, it was later discovered that the SARS-CoV-2 virus binds to the ACE2 receptor, an important receptor present on the surface of testosterone-producing Leydig cells. Thus, temporary testosterone deficiency is a direct impact of COVID-19 infection. Dr. Ramasamy advises his recovered patients to naturally increase their testosterone levels by eating, exercising, and sleeping well. COVID-19 is also linked to higher rates of erectile dysfunction. Dr. Ramasamy explains that the cause of ED may not be psychogenic, as the SARS-CoV-2 virus affects endothelial cells lining blood vessels. Studies have also shown that the virus can be present in penile tissue seven to 9 months post-infection. As a result, Dr. Ramasamy urges urologists to differentiate between psychogenic and vasculogenic erectile dysfunction. Next, the doctors discuss the impact of COVID-19 on fertility. Research has shown that a COVID-19 infection may decrease sperm count in semen three to six months post-infection. Most patients have normal sperm counts after 6 months. Although birth rates have declined due to the uncertainty during the pandemic, Dr. Ramasamy notes that more male patients have requested fertility consultations with him as a proactive family planning measure. Finally, Dr. Ramasamy uses evidence-based medicine to debunk myths about the mRNA COVID-19 vaccination on male sexual and gonadal function. He cites his most recently published article, “Sperm Parameters Before and After COVID-19 mRNA Vaccination” (JAMA) and emphasizes that there is no link between the vaccine and declining sperm count.

Dr Maheshi Ramasamy is a Principal Investigator at the Oxford Vaccine Group where she leads on adult clinical vaccine trials including the Oxford AstraZeneca COVID-19 vaccine trials. Dr Ramasamy joins the podcast from the UK to take us through the challenges of developing a successful international clinical trial against the clock during a fast-moving pandemic, her experiences as a clinician scientist working on the frontline in UK COVID hospital wards and the impact of securing approval for the vaccine. MTPConnect co-hosts MD and CEO Dr Dan Grant and COO Stuart Dignam chat to Dr Ramasamy about concerns over vaccine safety, rare adverse events, vaccine hesitancy and fake news. Dr Ramasamy, an Australian Sri Lankan, shares her motivations and research interests. She also explains how her international career pathway – including working at Australia's Ballarat Base Hospital - helped her to pursue this challenge of a lifetime. Dr Ramasamy is also a Consultant Physician at Oxford University Hospitals NHS Foundation Trust, the Deputy Director of the Graduate Entry Medicine course at Oxford and the Florey Lecturer at Oxford's Magdalen College. 

In this medical education podcast series, myeloma experts Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute at the Icahn School of Medicine and the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, USA) and Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London, UK) discuss their experience and views on choosing the best treatment every time in multiple myeloma. In this first episode, Dr. Richter and Dr. Ramasamy discuss how to select the best approach in newly diagnosed patients with multiple myeloma. The experts look at transplant eligibility as one of the key factors in deciding which treatment to start with in the front-line setting. They discuss the potential for personalising therapy in newly diagnosed patients, both in the transplant setting as well as in patients who are not eligible for transplantation. They also comment on the impact of MRD negativity in clinical practice and agree that the goal of treatment is to induce deep remissions. However, which patient needs triple or quadruplet therapy to achieve this goal is still unclear and the risk-benefit profile needs to be considered for each individual patient. The final topic that the experts share their points of view on is continuous vs fixed-duration maintenance therapy.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: the Star Wars editor is not happy about the sequel trilogy, Neil Druckmann is one of the directors of The Last Of Us HBO Series, the Obi Wan TV series has completed filming as confirmed by Ewan McGregor and The Flash movie director teases Batman's crossover. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: The trailer for the new Matrix movie is finally here, God Of War Ragnarok has revealed the gameplay trailer, a new look at Spider Man 2 for the PS5 and the Spider-Verse sequel writer started working on the film before the original came out. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

Shri K Ramasamy is an entrepreneur, and long-time devotee of Sri Swami Satchidanada. Mr. Ramasamy is the President of Integral Yoga Institute in Coimbatore India, as well as the managing trustee of Satchidananda Jothi Nikethan International School in India. See acast.com/privacy for privacy and opt-out information.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: Ed Asner kicking the bucket, the Cowboy Bebop live action show gets a prequel novelization, Halo Infinite campaign wasn't shown during Gamescom and Manifest is saved by Netflix for one more season. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

On this week's episode of Hero Time, Russell Ramasamy will be reporting on the hottest topics in the world of Pop Culture, including: the Magic The Gathering animated series loses Avengers Endgame directors, The Navy prevented Tom Cruise from flying a jet for Top Gun 2, The Black Canary solo movie is in the works and the teaser for Spider Man: No Way Home has finally arrived with "Marvelous" information All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

A special video / podcast marking the 5th anniversary of 'Dharmadurai' release. Watch the video in our YT channel!

This episode is also available as a blog post: https://jnmanokaran.wordpress.com/2021/07/11/book-review-periyar-e-v-ramasamy-a-man-ahead-of-his-time/

Why did Ramasamy decide to sell his farm? Why were the buyers reluctant to get it? To whom did Ramasamy finally sell the farm? Why did he want to get back his farm from Meiappan? Why did Meiappan decide to take the case to King's court? What did the King order? What was the Minister's judgment?ராமசாமி தன்னுடைய தென்னந்தோப்பை ஏன் விற்க முயற்சித்தார்? அதை வாங்க ஏன் எல்லோரும் தயங்கினார்கள்? கடைசியில் அவர் யாரிடம் விற்றார்? மெய்யப்பனிடம் இருந்து அதை திரும்ப பெற ஏன் ராமசாமி முடிவெடுத்தார்? மெய்யப்பன் ஏன் வழக்கை அரசனிடம் கொண்டு சென்றார்? அரசனின் முடிவு என்ன? அமைச்சர் என்ன தீர்ப்பு அளித்தார்?You can listen to this awesome story on Story Time Tamil Youtube Channel: https://youtu.be/q5IT5XoH5Xs You can listen to this show and other awesome shows on the IVM Podcasts app on Android: https://ivm.today/android or iOS: https://ivm.today/ios, or any other podcast app.You can check out our website at http://www.ivmpodcasts.com

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including: Merle Dandridge reprises her role in The Last Of Us HBO Series, new details on Horizon Forbidden West, the sequel to Joker is in the works and the character of Okoye is in the Black Panther Disney Plus series. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including: Kevin Feige's words on The Ancient One's casting, Martin Freeman has things to say about Jim Carrey's Man On The Moon method acting, The Sonic The Hedgehog 2 movie plot synopsis has been leaked and the sequel to Hocus Pocus is in development on Disney Plus. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including Logan star, Boyd Holbrook joins Indiana Jones 5 as the antagonist, Michael Jordan to appear in Space Jam 2, Dave Bautista pitches the idea of the Gears of War movie and new Details on the most anticipated Friends reunion special. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

Prolific social activist and crusader K R Ramaswamy, popularly known as Traffic Ramaswamy, passed away on Tuesday in Chennai. He was 87. RaySel presents a feature on Ramasamy. - தமிழ்நாட்டில் அரசை எதிர்த்தும், அதன் அதிகாரங்களை எதிர்த்தும் ஒரு அமைப்பாக இல்லாமல் தனி நபராக களத்தில், கலகக்காரராக அச்சமின்றி செயல்பட்டு, போராடி “ட்ராஃபிக்” ராமசாமியாக அறியப்பட்ட சமூக செயல்பாட்டாளர் “ட்ராஃபிக்” ராமசாமி அவர்கள் இந்த வாரம் மறைந்தார். அவர் குறித்த விவரணத்தை முன்வைக்கிறார் றைசெல்.

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including: The new Captain America movie in the works from The Falcon and the Winter Soldier showrunner at the helm, new details on the John Wick TV spinoff, The Continental has been revealed, Jason Statham talks the return of a major character in Fast and Furious 9 and the Oscar winning movie, Parasite is getting a TV adaptation set in the same universe as the film. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including Alfred Molina returning to the role of Doc Ock in Spider Man: No Way Home, the new trailer for Shang Chi and the Legend of the Ten Rings is here and it's action packed, the writers of the hit movie, Predator are taking Disney to court over who gets the rights to the franchise and The Last of Us HBO series hires Gabriel Luna to play main protagonist's younger brother. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

Dr. Ranjith Ramasamy, joins us to discuss what a typical visit to a urologist might look like for a patient facing erectile dysfunction (ED). Dr. Ramasamy is a urologist and serves as Director of Male Reproductive Medicine and Surgery, and Associate Professor in the Department of Urology at the Miller School of Medicine at the University of Miami Health System in Florida. In addition to ED, his area's of expertise include: Vasectomy and Vasectomy Reversal Male Infertility Low Testosterone Peyronies disease Fertility Preservation  He can be reached via email at ramasamy@miami.edu. The Erectile Dysfunction Radio Podcast is dedicated to educating and empowering men to address erectile dysfunction, improve confidence, and enhance the satisfaction in their relationships. This podcast is hosted by certified sex therapist, Mark Goldberg, LCMFT, CST. Learn more by visiting ErectionIQ.com. 

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including The Last Of Us video game is getting another remake treatment along the pitch for the Days Gone sequel rejected, Phoebe Waller-Bridge joins Harrison Ford for the James Mangold directed Indiana Jones 5, Paramount Pictures has delayed numerous movies such as Top Gun Maverick, Mission Impossible 7 and 8 and more and Michael B Jordan explained why Sylvester Stallone won’t be returning for Creed 3 as Rocky Balboa. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

This week on Hero Time, Russell Ramasamy bringing reports straight from the world of Pop Culture, including The Last Of Us HBO series will start production in July in Canada, John Woo adapts one of the late legendary, Stan Lee's lost stories, Monkey Master into live action, the Black Widow trailer has been released and revealed a new release date and the inside look at the first trailer for Space Jam: A New Legacy. All on this week's episode of Hero Time with Russell Ramasamy, bringing all the latest in pop culture news for your hearing pleasure.

நாலடியார் நவிலும் நன்னெறிகள். இலக்கியத்துளிகள்-நாலடியாரில் – பொருட்பாலில், அரசு இயலில் தாளாண்மை அதிகாரம் – விடா முயற்சியின் சிறப்புனை விளக்கும் வெண்பாக்கள் மற்றும் அவற்றின் விளக்கங்கள் -தொடர் முயற்சியின் சிறப்பை வலியுறுத்தி சமணமுனிவர்கள் எழுதியுள்ள கருத்துகளை விளக்கும் தெரிந்து எடுக்கப்பட்ட வெண்பாக்கள்- Thaalaanmai-Vidaamuyarchi-தாளாண்மை – விடாமுயற்சி-மார்ச் 14, 2021. --- Support this podcast: https://anchor.fm/americantamilradio/support

E.V. Ramasamy promoted the principles of rationalism, self-respect, women's rights and eradication of caste. He opposed the exploitation and marginalisation of the non-Brahmin Dravidian people of South India and the imposition of what he considered Indo-Aryan India.

Masters Selections; For Loved Ones. Every year, hundreds of students apply for various Psychology Masters programmes around South Africa. Students pour their hearts and minds into applications and autobiographies in the hopes that a university will select them to interview for a space in the class of the following year. While this time is stressful for the students, the family support systems of these students is of put under tremendous strain too. This podcast was created in order to help the families and loved ones of these brave students understand the selection process and what the students are trying to achieve.  We have asked Dr Kameshnee Ramasamy, a Clinical Psychologist from Nelson Mandela University, to help us understand some of the behind-the-scenes procedures that make selections the way they are. We also look into the reasons as to why these selections need to be as stringent as they have become over the past few years.  If you're an applicant and you want someone in your support system to understand what you're going through, have them listen to this podcast (maybe even with you); this one is for the loved ones.  Dr Ramasamy runs a Private Practice in Port Elizabeth - 39 Fourth Avenue, Newton Park (041 365 7750). She has also had a massive involvement in the Enthomjeni - Fountain of Student Wellness project at NMU. Click the link above for more details on that initiative.  The Cognition & Co Podcast is now available on all major Podcast Streaming Apps so make sure you subscribe in order to keep hearing our content. Follow our social media pages by clicking the links below; Facebook Instagram Twitter If anyone is interested in sponsoring an episode of the Cognition & Co Podcast, please contact us by following this link. Visit our website for more information on our services and offerings - www.cognitionandco.com

This episode is a discussion about the fascinating and ground breaking views of the dravidian stalwart Periyar E.V. Ramasamy in his book “பெண் ஏன் அடிமையானாள்?” --- Send in a voice message: https://anchor.fm/vina-podcast/message

National Libraries Day 2020| National Libraries Day August 12| Librarian- Dr.K.Ramasamy, Government Arts and Science College

#KDEngiraKaruppuDurai (https://www.youtube.com/results?search_query=%23KDEngiraKaruppuDurai) is a Tamil Movie. Written & Directed by Madhumita, Starring Mu. Ramasamy, Nagavishal, Yog Japee. The music is composed by Karthikeya Murthy and cinematography was handled by Meyyendiran Kempuraj.

Did you think that only women underwent Menopause. Well men do that too and it's called Manopause or Late Onset Hypogonadism (LOH). As we age men undergo certain changes and one of them is lowering of testosterone. Research finds out that this lack of testosterone can suck the marrow out of your life by increasing lethargy, grumpiness and boredom and reducing your performance between the sheets and even your height. Now all this is reversible if we keep our youth nourished and upto mark. Ranjith Ramasamy is the Director of Male Reproductive Medicine and Surgery as well as an Associate Professor in the Department of Urology at the University of Miami in Florida and in this episode with leading andrologist and host Dr. Raman Tanwar, he shares his experience with late onset hypogonadism or Manopause. If you have symptoms like decrease in libido, lack of energy, decrease in strength and/or endurance, loss of height, decreased "enjoyment of life", Feeling sad and/or grumpy?, poor erections, recent deterioration in your ability to play sports, falling asleep after dinner or recent deterioration in your work performance then its time you got your Testosterone checked too. The symptoms that we've mentioned here are those of Manopause and the decrease in testosterone is what is responsible for most of it in many cases. Luckily if identified this condition can be controlled with supplementation with Testosterone, but it needs to be in the right dose and by the right expert with the right monitoring. Also this condition unlike menopause is not inevitable. Manopause can be prevented by lifestyle change early on and in this episode we will discuss all that and more.

Sai Giridhar Ramasamy joins us and shares his unique approach to implementing AI: "We don't go to our traditional IT and get any results out of them or try and get results out of them, but then we have our own machine learning team, which we call the machine intelligence program, under which we have various intelligence automation, robotic process automation labs, that we try and think and come up with new ways of doing things, and we have the flexibility to test it."